Active pharmaceutical ingredients (APIs) and excipients are the two most important components in the production of a medication. API is the raw material, which is used in manufacturing medications, whereas excipient is a substance that functions as a medium to help the body absorb the drug such as lactose or mineral oil in a tablet. Active pharmaceutical ingredients are produced by using highly technological industrial processes, both during the research & development and commercial production phases. Such compounds are developed to provide pharmacological activity or other direct impacts on disease diagnosis, cure, mitigation, therapy, or prevention, or to change the structure and function of the body. The growth of active pharmaceutical ingredient (API) market can be attributed to certain factors such as increasing funding initiatives by the government across different regions. For instance, in May 2020, the U.S. Department of Health and Human Services (HHS) announced that it will provide a funding of US$ 354 million to Phlow Corporation, a pharmaceutical company, under a four-year contract to produce the active pharmaceutical ingredients (APIs) needed for medications to treat patients with COVID-19 and related illnesses.
Market Dynamics
The rising U.S Food & Drug Administration (FDA) approvals for drugs by pharmaceutical companies is further expected to boost the global active pharmaceutical ingredient (API) market growth during the forecast period. For instance, in December 2020, Eily Lilly received the U.S FDA clearance for several medicines including increased dosages of its Trulicity therapy for the treatment of type 2 diabetes, Cyramza for the treatment of metastatic Estimated Glomerular Filteration Rate (EGFR)-mutated non-small cell lung cancer, and tauvid for individuals diagnosed with Alzheimer's disease.
Key features of the study:
- This report provides an in-depth analysis of the global active pharmaceutical ingredient (API) market, and provides market size (US$ Bn) and compound annual growth rate (CAGR%) for the forecast period (2021–2028), considering 2020 as the base year
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global active pharmaceutical ingredient (API) market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, strategies
- Key companies covered as a part of this study include Teva Pharmaceutical Industries Ltd., Pfizer, Inc., Dr. Reddy’s Laboratories Ltd., Novartis AG, Mylan N.V., Amneal Pharmaceuticals LLC, Lonza Group, Lupin Limited, Fresenius Kabi, Hikma Pharmaceuticals, Cipla Limited, Glenmark Pharmaceuticals Limited, Sun Pharmaceutical Industries Ltd., Endo International plc, Aurobindo Pharma Limited, Apotex Inc, Taro Pharmaceutical Industries Ltd, Stada Arzneimittel AG, Krka Pharmaceuticals, CordenPharma International, Evonik Industries AG, and Biological E. Limited
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- The global active pharmaceutical ingredient (API) market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have an ease in decision-making through various strategy matrices used in analyzing the global active pharmaceutical ingredient (API) market
Detailed Segmentation:
- Global Active Pharmaceutical Ingredient (API) Market, By Product Type:
- Low Potent APIs
- High Potent APIs
- Global Active Pharmaceutical Ingredient (API) Market, By Molecular Type:
- Small Molecules
- Large Molecules
- Global Active Pharmaceutical Ingredient (API) Market, By Formulation:
- Oral
- Topical
- Injectable
- Drops
- Global Active Pharmaceutical Ingredient (API) Market, By Application:
- Diabetes
- Oncology
- Cardiovascular
- CNS
- Analgesics
- Ophthalmic
- Respiratory
- Dermatology
- Others
- Global Active Pharmaceutical Ingredient (API) Market, By Region:
- North America
- By Product Type
- Low Potent APIs
- High Potent APIs
- By Molecular Type
- Small Molecules
- Large Molecules
- By Formulation
- Oral
- Topical
- Injectables
- Drops
- By Application
- Diabetes
- Oncology
- Cardiovascular
- CNS
- Analgesics
- Ophthalmic
- Respiratory
- Dermatology
- Others
- By Country
- Latin America
- By Product Type
- Low Potent APIs
- High Potent APIs
- By Molecular Type
- Small Molecules
- Large Molecules
- By Formulation
- Oral
- Topical
- Injectables
- Drops
- By Application
- Diabetes
- Oncology
- Cardiovascular
- CNS
- Analgesics
- Ophthalmic
- Respiratory
- Dermatology
- Others
- By Country
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- By Product Type
- Low Potent APIs
- High Potent APIs
- By Molecular Type
- Small Molecules
- Large Molecules
- By Formulation
- Oral
- Topical
- Injectables
- Drops
- By Application
- Diabetes
- Oncology
- Cardiovascular
- CNS
- Analgesics
- Ophthalmic
- Respiratory
- Dermatology
- Others
- By Country
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- By Product Type
- Low Potent APIs
- High Potent APIs
- By Molecular Type
- Small Molecules
- Large Molecules
- By Formulation
- Oral
- Topical
- Injectables
- Drops
- By Application
- Diabetes
- Oncology
- Cardiovascular
- CNS
- Analgesics
- Ophthalmic
- Respiratory
- Dermatology
- Others
- By Country
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- By Product Type
- Low Potent APIs
- High Potent APIs
- By Molecular Type
- Small Molecules
- Large Molecules
- By Formulation
- Oral
- Topical
- Injectables
- Drops
- By Application
- Diabetes
- Oncology
- Cardiovascular
- CNS
- Analgesics
- Ophthalmic
- Respiratory
- Dermatology
- Others
- By Country
- GCC
- Israel
- Rest of Middle East
- Africa
- By Product Type
- Low Potent APIs
- High Potent APIs
- By Molecular Type
- Small Molecules
- Large Molecules
- By Formulation
- Oral
- Topical
- Injectables
- Drops
- By Application
- Diabetes
- Oncology
- Cardiovascular
- CNS
- Analgesics
- Ophthalmic
- Respiratory
- Dermatology
- Others
- By Country/Region
- South Africa
- Central Africa
- North Africa
- Company Profiles
-
- Teva Pharmaceutical Industries Ltd.*
- Company Highlights
- Products Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Pfizer, Inc.
- Reddy’s Laboratories Ltd.
- Novartis AG
- Mylan N.V.
- Amneal Pharmaceuticals LLC
- Lonza Group
- Lupin Limited
- Fresenius Kabi
- Hikma Pharmaceuticals
- Cipla Limited
- Glenmark Pharmaceuticals Limited
- Sun Pharmaceutical Industries Ltd.
- Endo International plc
- Aurobindo Pharma Limited
- Apotex Inc.
- Taro Pharmaceutical Industries Ltd
- Stada Arzneimittel AG
- Krka Pharmaceuticals
- CordenPharma International
- Evonik Industries AG
- Biological E. Limited
“*” marked represents similar segmentation in other categories in the respective section.
